Evidence map›Paper›PMID 31073549›Full record

ArticleJCO precision oncology2018

New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare.

K A Phillips, J R Trosman, C B Weldon, M P Douglas

Abstract readComment
In one paragraph

Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

K A PhillipsUniversity of California at San Francisco, Department of Clinical Pharmacy.
J R TrosmanUniversity of California at San Francisco, Department of Clinical Pharmacy.
C B WeldonCenter for Translational and Policy Research on Personalized Medicine (TRANSPERS).
M P DouglasUniversity of California at San Francisco, Department of Clinical Pharmacy.

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Sharing Aggregate Genomics Research Findings with Diverse Participants: A Pilot Study of an Innovative Design StrategyU01HG009599 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOENIG, BARBARA A., KWOK, PUI-YAN · 2017 to 2021
$16.3M
Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5M
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related ConditionsR01CA221870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2018 to 2020
$2.2M
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA221870NHGRI NIH HHS R01 HG007063NHGRI NIH HHS U01 HG009599
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31073549
PMCPMC6503521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.